BiomarkersInosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients

Add time:09/06/2019    Source:sciencedirect.com

We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient–donor pairs after nonmyeloablative hematopoietic cell transplant (HCT). Patients were conditioned with total body irradiation + fludarabine and received grafts from related or unrelated donors (10% HLA mismatch), with postgraft immunosuppression of mycophenolate mofetil (MMF) with a calcineurin inhibitor. Recipient and donor IMPDH genotypes (rs11706052, rs2278294, rs2278293) were not associated with day 28 T cell chimerism, acute graft-versus-host disease (GVHD), disease relapse, cytomegalovirus reactivation, nonrelapse mortality, or overall survival. Recipient IMPDH1 rs2278293 genotype was associated with a lower incidence of chronic GVHD (hazard ratio, .72; P = .008) in nonmyeloablative HCT recipients. Additional studies are needed to confirm these results with the goal of identifying predictive biomarkers to MMF that lower GVHD.

We also recommend Trading Suppliers and Manufacturers of 2'-(5''-phosphoribosyl)-5'-adenosine monophosphate (cas 15720-01-1). Pls Click Website Link as below: cas 15720-01-1 suppliers

Prev:The catalytic effect of Mg2+ and imidazole on the decomposition of 5-phosphoribosyl-α-1-pyrophosphate in aqueous solution
Next:Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates)